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This paper describes the synthesis and characterization of N5-(hetero)arylalkyl-substituted-
thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives (4-19) as novel human (h) A2A adenosine 
receptor (AR) inverse agonists. Competition binding and cyclic AMP assays indicate that the 
examined compounds behave as hA2A AR inverse agonists showing binding affinity values in the 
nanomolar or subnanomolar range. Notably, compounds 4, 5, 6 and 11 showed two affinity values 
for the hA2A ARs with the highest (KH) falling in the femtomolar range and the lowest (KL) of 
the nanomolar order. In addition, in cyclic AMP assays, compounds 4, 5, 6 and 11 exibited potency 
(IC50) values in the picomolar range. 
This study has confirmed that 2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based 
derivatives represent a unique new class of hA2A AR inverse agonists. 
 
KEYWORDS. G protein coupled receptors; A2A adenosine receptors; inverse agonists; 
thiazolopyrimidine derivatives; bicyclic heteroaromatic system. 
 
ABBREVIATIONS. AR, adenosine receptor; cAMP, 3’,5’-cyclic adenosine monophosphate; 
CHO, chinese hamster ovary; DPCPX, 8-cyclopentyl-1,3-dipropyl-xanthine; I-AB-MECA, 4-[((4-
amino-3-iodophenyl)methyl)amino]-5’-N-methylcarboxamidoadenosine; 1, (4-(2-[7-amino-2-(2-
furil)[1,2.4] triazolo[2,3-a][1,3,5]triazin-5-ylamino] ethyl) phenol); 28, 2-p-(2-carboxyethyl) 
phenethylamino-5’-N-ethylcarboxamidoadenosine; NECA, 5’-N-ethyl-carboxamidoadenosine; 
AB-MECA, 4-[((4-aminophenyl)methyl)amino]-5’-N-methylcarboxamidoadenosine; TCA, 
trichloroacetic acid; MW, microwave. 
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1. Introduction 
The ubiquitous nucleoside adenosine mediates several effects, mainly through interaction with 
four G-protein coupled receptors, named A1, A2A, A2B and A3 adenosine receptors (ARs), 
expressed in several cells and tissues [1]. ARs have been well characterized from a structural point 
of view, for their cellular and tissue distribution and for their physiological effects. Cell signaling 
transduction pathways following ARs activation are primarily linked to cyclic adenosine 
monophosphate (cAMP) modulation. In particular, A1 and A3 ARs are negatively coupled with 
adenylyl cyclase and exert an inhibitory effect on cAMP production, while A2A and A2B ARs 
stimulate adenylyl cyclase activity inducing an increase in cAMP levels [1]. Several papers present 
in the literature have suggested that ARs are implicated in numerous pathological functions, and 
fundamental in severe human diseases such as neurodegenerative and cardiovascular disorders, 
inflammatory diseases, and cancer [2, 3]. Moreover, extracellular adenosine concentration is 
significantly increased under conditions of hypoxia, ischemia or high metabolism that typically 
occur in pathological or stressful situations thereby enabling to enhance activation of ARs under 
these pathological conditions [3, 4]. This intriguing scenario has suggested to researchers the 
development of molecules able to bind ARs as novel potential drugs [5-8]. 
Several ligands have been developed up to now having a wide spectrum of activity such as 
agonists/partial agonists, allosteric enhancers, antagonists and/or inverse agonists [8]. However, 
the complexity of AR signaling, due to the widespread distribution of the receptors in the body 
and the redundancy of their effects, is responsible for the limited number of AR drugs 
commercially available. Nowadays, an A2A AR agonist (Regadenoson from CV Therapeutics & 
Astellas) is approved for computed tomography myocardial and coronary artery perfusion imaging 
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[9] and an A2A AR antagonist (Istradefylline from Kyowa Hakko Kirin Co) in Japan is used for the 
treatment of Parkinson’s disease [10]. 
As a part of our efforts to identify novel human (h) AR antagonists [11-17], we recently reported 
on the development of compounds bearing the thiazolo[5,4-d]pyrimidine nucleus [18,19]. In detail, 
taking the well known hA2A AR selective inverse agonist 1 (ZM 241385) [20] as lead compound, 
a small library of 2-(2-furanyl)-thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives was 
synthesized and tested, leading to the identification of two compounds, 2 and 3, which resulted 
highly selective  hA2A AR inverse agonists more potent than 1 (Figure 1) [19]. 
(Figure 1) 
Notably, in [3H]-1 ( [3H]-ZM 241385) competition binding experiments, compounds 2 and 3 were 
characterized by two different affinity values (KH and KL) for hA2A AR with high affinity (KH) 
value in the femtomolar range and low affinity (KL) value of nanomolar order. Furthermore, 
thiazolopyrimidines 2 and 3 were also tested in in vivo murine models of acute pain, showing an 
antinociceptive activity equal to or greater than morphine [19].  
Derivatives 2 and 3, although showing nanomolar affinities for hA1 and hA3 ARs and good 
potencies for the hA2B subtype, due to their hA2A femtomolar affinities, can be considered the most 
potent and selective hA2A AR inverse agonists reported so far. These results encouraged us to 
further investigate the structure-activity relationships within this series. Hence, we herein report 
the design and pharmacological characterization of novel 2-(2-furanyl)-thiazolo[5,4-d]pyrimidine-
5,7-diamine derivatives (4-13) substituted at the N5 nitrogen atom with a heteroarylalkyl chain 
(Figure 1). Modifications at this level were performed by varying the nature and position of the 
heteroatom and the length of the alkyl chain to shed more light on the steric and electronic 
requirements of the hA2A binding site. 
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Next, we focused our attention toward replacement of the 2-(2-furanyl) moiety in order to probe 
the interactions between the substituent at this position and the receptor cleft. Thus, we synthesized 
compounds 14-19 in which the 2-(2-furanyl) ring of 2, 3 and 4 was replaced by a 2-(5-methyl-2-




N5-(Hetero)arylalkyl-thiazolo[5,4-d]pyrimidine-5,7-diamine derivatives 4-19 were obtained by 
reacting the 7-amino-5-chloro-thiazolo[5,4-d]pyrimidine derivatives 20 [19], 21-22 with the 
(hetero)arylalkylamines of interest, under microwave irradiation at 200 °C (Scheme 1). All the 
employed amines were commercial except for the 2-(2-furanyl)ethylamine which was synthesized 
starting from the furan-2-carboxyaldheyde according to literature data [21]. 
(Scheme 1) 
The 7-amino-5-chloro derivative 20 was synthesized as previously reported [19]. Similarly, 
compounds 21-22 were obtained starting from the 5-amino-6-sulfanylpyridine-2,4-diol 23 [22] 
which reacted with acyl chlorides of interest in NMP at 160 °C to afford the bicyclic thiazolo[5,4-
d]pyrimidine-5,7-diol derivatives 24-25 (Scheme 2). Reaction of these latter with POCl3 afforded 
the corresponding 5,7-dichloro substituted compounds 26-27 which were treated with a 33% 






3. Results and discussion  
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Derivatives 4-19 were pharmacologically evaluated at hA1, hA2A, hA2B, and hA3 ARs stably 
expressed in Chinese hamster ovary (CHO) cells by using competition binding and cyclic AMP 
assays.  
The affinity for hA1, hA2A, and hA3 AR (expressed as Ki values) and the potency for the hA2B AR 
(expressed as IC50 values) of the novel compounds 4-19 are displayed in Table 1. The affinity and 
potency data of the previously reported thiazolopyrimidines 2 and 3 and of the triazolotriazine 1, 
as reference compounds are also reported (Table 1). 
(Table 1) 
Thiazolo[5,4-d]pyrimidines 4-13 bearing a (2-furanyl) moiety at position 2 of the bicyclic core 
have been found to be very potent ligands at the hA2A AR. Most notably, compounds 4, 5, 6, and 
11 showed, like references 2 and 3, two affinity values for the A2A subtype: the highest (KH) in 
the femtomolar range, the lowest (KL) of nanomolar order. Also the other novel 2-(2-furanyl)-
thiazolopyrimidines (7-10, 12-13) proved to be highly potent at the hA2A subtype, showing binding 
affinities in the subnanomolar (7, 8, 13) or low nanomolar range (9, 10, 12). 
Most of the 2-(2-furanyl) substituted compounds 4-13 also possessed nanomolar affinity for the 
hA1 and hA3 subtypes, except compounds 9, 10, and 13 which bind the hA3 AR receptor with a Ki 
> 100 nM. It is worth noting that compounds 4-13 also interact with the hA2B AR, showing 
potencies in the nanomolar range, 7 and 13 being the most potent with IC50 values of 8.96 nM and 
4.21 nM, respectively. 
Analyzing the binding results in detail, when R2 = 2-furanyl and R5 = CH2-heteroaryl (compounds 
4-10), the presence of a 2-thienyl (4), 2-furanyl (5), or 3-pyridyl (6) group in R5 affords a very 
high KH value for the hA2A AR (KH = 10.7 fM (4), 39 fM (5), and 217 fM (6)) and a KL value of 
the nanomolar order (KL = 3.82 nM (4), 1.73 nM (5), and 0.68 nM (6)). As stated above, 
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derivatives 4, 5, and 6 also bind the other hARs but, due to their hA2A femtomolar affinities, they 
can be considered extremely selective ligands for this subtype. 
Movement of the heteroatom of the appended R5 substituent of derivatives 4 and 6 resulted in the 
loss of the double affinity for the hA2A receptor. In fact, derivative 7, which bears a  (3-thienyl) 
moiety at R5, shows one affinity value which however falls in the subnanomolar range (Ki = 0.25 
nM). The same applies to the N5-(2-pyridyl)methyl and the N5-(4-pyridyl)methyl derivatives 8 and 
9 which maintain binding affinities in the sub or nanomolar range (Ki =0.42 nM (8), and Ki = 12 
nM (9)). Also the presence of the 2-pyrazinyl ring in R5  (compound 10) is profitable for hA2A AR 
receptor interaction  (Ki = 5.14 nM). 
In general, derivatives 7-10 also bind the other hAR subtypes well, exhibiting affinities and 
potencies in the nanomolar range. In particular, the N5-(3-thienyl)methyl derivative 7 is the most 
interesting since its high affinities at all the hARs make it a potent and balanced pan-hAR ligand.  
Homologation of the methylene linker of the lateral chain of compounds 4, 5, and 6 yielded the 
corresponding N5-ethyl derivatives 11-13. The N5-(2-thienyl)ethyl derivative 11 maintains the 
double affinity at the hA2A AR being, like its N
5-(2-thienyl)methyl analogue 4, an extremely 
selective hA2A AR ligand with a high affinity value in the femtomolar range (KH=10.6 fM).  
Instead, the N5-(2-furanyl)ethyl (12) and the N5-(3-pyridyl)ethyl derivatives (13), differently from 
their corresponding inferior homologous 5 and 6, show one affinity value for the hA2A AR receptor 
in the nanomolar and subnanomolar range (Ki =2.15 nM (12), and Ki = 0.24 nM (13)). Moreover, 
they too bind all hARs with affinities and potencies ranging from low to high nanomolar range, 
thus behaving as pan-AR ligands. 
When the 2-(2-furanyl) group of compounds 2, 3, and 4 was substituted with a 2-(5-methyl-2-
furanyl) moiety, a significant drop of hAR affinities was obtained. In fact, compounds 14-16 not 
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only lose the double affinity for the hA2A subtype, but also exhibit a decreased capability to bind 
all hARs, with respect to the references 2, 3 and 4. These data clearly indicate that the presence of 
a small group on the 2-(2-furanyl) moiety negatively influences the interaction of thiazolo[5,4-
d]pyrimidine-5,7-diamine-based derivatives with all the hAR subtypes. Instead, replacement of 
the 2-(2-furanyl) substituent of 2, 3, and 4 with the isostere 2-(2-thienyl) group affords compounds 
17-19 which, although losing the double hA2A affinity of the references 2, 3, and 4 , maintain a 
hA2A binding affinity in the low nanomolar range. 
Figure 2 shows the competition curves of compounds 4, 5, 6, and 11 which displayed biphasic 
profiles whereas the other thiazolopyrimidines 7-10, 12-19 presented monophasic inhibition 
curves (Table 1). 
(Figure 2) 
The biphasic profile observed for compounds 4, 5, 6, and 11 and for the references 2 and 3 [19], 
may be interpreted on the basis of the extended ternary complex model of receptor action. 
According to this model, a receptor can exist as an equilibrium of different conformational states 
that include the inactive state (R), partly activated forms (R*) and the activated form coupled to G 
protein (R*G). Certain compounds may be able to differentiate some of these receptor 
conformations. However, according to this model, neutral antagonists present the same affinity for 
the different receptor states/conformations and should not recognize different receptor states [23-
24]. Therefore, the discrimination of receptor subpopulations by compounds 4, 5, 6, and 11 
prompted us to verify their behavior by evaluating their antagonist/inverse agonist potencies at the 
hA2A AR in functional in vitro assays. 
Thus, compounds 4-13, 17, 19 were tested to assess their ability to modulate cAMP production in 
basal conditions or in the presence of the full agonist 28 (CGS 21680) which showed an EC50 of 
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12±2 nM and Emax of 100%  [25]. The data are presented in Table 2 together with those of 
references 2, 3 and 1. 
 (Table 2) 
All the examined compounds were able to inhibit basal cAMP accumulation, thus they all behave 
as inverse agonists. In particular, compounds 4, 5, 6, and 11 show IC50 values from 11 to 1.6 pM 
(Table 2) with efficacy values (Emax) from 61% to 64% (Figure 3, Table 2). It should be noted 
that compounds 4, 5, 6 and 11 are very potent inverse agonists, comparable to 2 and 3, with 
potencies 103-fold greater than that of 1 (IC50 = 1.24 nM). Moreover, according to their 
subnanomolar hA2A AR affinity, compounds 7, 8, and 13 were found to inhibit basal cAMP 
accumulation with IC50 values from 0.29 to 0.68 nM (Table 2), which are slightly greater than that 
of 1. 
(Figure 3) 
Moreover, all the texted compounds were also able to inhibit cAMP production stimulated by the 
agonist 28 (10 nM) thus revealing, as expected, an antagonist/inverse agonist profile. In particular, 
these compounds were able to reduce the cAMP accumulation over the basal level as indicated by 
Emax data (from 115 to 141 %, Table 2). As above, compounds 4, 5, 6, and 11 blocked the effect 
of the agonist with potency values (IC50 values from 36 to 59 pM, Table 2) comparable to those of 
2 and 3 (IC50 = 51, and 95 pM, respectively) and greater than that of 1 (IC50 = 0.83 nM). Notably, 
they were able not only to block the agonist effect but also to inhibit the constitutive activity of the 
receptor. In fact, as shown in Figure 4, compounds 4, 5, 6, and 11 achieve negative levels of cAMP 
accumulation below the basal cAMP production, which in this experiment is set at zero. 
(Figure 4) 
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Finally, it has to be noted that compounds which show monophasic competition curves (7-10, 12, 
13, 17 , 19 and the reference 1) displayed in the cAMP assays similar IC50 values in the presence 
and absence of the agonist. In contrast, compounds 4, 5, 6 and 11 as well as the references 2 and 
3, which show a biphasic binding profile, resulted to be more potent in the absence of the agonist. 
Furhermore, the inhibition curve of compounds 4, 5, 6 and 11 obtained in cAMP assays showed 
monophasic pattern in contrast to the biphasic curve found in binding assays. This is most likely 
due to the characteristics of the binding assay that highlight the specific interaction between the 
examined compounds and the radioligand for the competition with the binding site. On the other 
hand, from the cAMP assay  it is possible to obtain informations on the effects of the compounds 
that represent a phase following ligand-receptor interaction. 
Additional experiments were carried out evaluating compounds 4-13, 17, and 19 in hA1, hA2B, or 
hA3 CHO cells to verify their effect on cAMP production in basal conditions. As indicated by the 
data in Table 3, none of the tested compounds have shown an inverse agonist profile for hA1, hA2B, 
and hA3 ARs. 
(Table 3) 
In order to ensure the druggability potential of compounds 4, 5, 6, and 11, their chemical and 
physical properties were determined in silico using pkCSM, an online tool for calculating small 
molecules pharmacokinetic properties [26]. Data reported in Table 4 show that compounds 4, 5, 
6, and 11 satisfied the typical drug-like characteristics (Lipinski “Rule of 5”) [27]. 
(Table 4) 
Moreover, compounds 4, 5, 6 and 11 possess other important predictors of good oral bioavailability 
such as a reduced molecular flexibility measured by the number of rotatable bonds, and a low polar 




In summary, by way of a conventional structure-affinity relationship study we discovered new 2-
(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives as hA2A AR inverse agonists 
characterized by binding affinities in the nanomolar or subnanomolar range. This study has 
confirmed that 2-(2-furanyl)thiazolo[5,4-d]pyrimidine-5,7-diamine-based derivatives represent a 
unique new class of hA2A AR inverse agonists. Notably, compounds 4, 5, 6, and 11, as well as the 
references 2 and 3, emerge as the most potent and selective hA2A AR inverse agonists reported so 
far with two affinity values for the A2A subtype the highest (KH) falling in the femtomolar range, 
and with potency (IC50) values in cyclic AMP assays of picomolar order. 
Pharmacological advantages of inverse agonism in different pathologies are well known due to 
their capability to inhibit the constitutive activity of the receptors. As a consequence, the 
availability of potent hA2A AR inverse agonists may help to clarify the clinical relevance of these 
compounds for the treatment of pain [19] and important diseases such as neurological disorders 
[6, 29], dermal fibrosis [30], retinal dysfunctions [31], and cancer [32]. 
 
5. Experimental section 
5.1. Chemistry  
Microwave-assisted synthesis were performed using an Initiator EXP Microwave Biotage 
instrument (frequency of irradiation: 2.45 GHz). Reactions were routinely monitored by thin-layer 
chromatography (TLC) on silica gel (0.20 mm, F254, Merck, Germany, aluminum sheets). Silica 
gel 60 (70-230 mesh, Merck, Germany) was used for column chromatography. Melting points 
were determined using  a Gallenkamp melting point instrument and are uncorrected. Compounds 
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were named following IUPAC rules as applied by ACD/ChemSketch. Elemental analyses were 
performed with a Flash E1112 Thermofinnigan elemental analyzer for C, H, N and the results are 
within ±0.4% of the theoretical values. 1H NMR and 13C NMR experiments were performed with 
a Bruker Avance 400 instrument (400 MHz for 1H and 100 MHz for 13C NMR). Spectra were 
recorded at 300 K, using DMSO-d6 as solvent. Peaks positions are given in parts per million using 
the residual non-deuterated solvent as the internal standard. Data are reported as follows: chemical 
shift (ppm), integrated intensity, multiplicity (indicated as: s, singlet; br s, broad singlet; exch, 
exchangeable proton with D2O; d, doublet; t, triplet; q, quartet; m, multiplet and combination 
thereof), coupling costants (J) values in Hertz (Hz). Scanned 1H and 13C NMR spectra of some 
selected compounds (4, 5, 6, 11, 15, 16, 17) are reported in the Supplementary data. 
5.1.1. General procedure for the synthesis of the 2-heteroaryl-N5-substituted-thiazolo[5,4-
d]pyrimidine-5,7-diamine derivatives (4-19)  
The proper amine (3 mmol) was added to a solution of the 5-chloro-7-amine derivatives 20 [19] 
or  21-22 (1 mmol) in n-BuOH (2 ml). The reaction mixture was microwave irradiated at 200 °C 
for 20 minutes, then cooled at rt and basified with aqueous KOH solution (50%). Addition of water 
afforded a solid which was collected by filtration and washed with Et2O. The crude material was 
purified by crystallization or by chromatography.  
5.1.1.1. 2-(Furan-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 4. 
Yield 78%. Mp 192-196 °C (isopropanol). 1H NMR: δ 4.64 (d, 2H, J = 6.2), 6.71-6.73 (m, 1H), 
6.93-6.95 (m, 1H), 6.99-7.00 (m, 1H), 7.06-7.07 (m, 1H), 7.23 (br s, exch 2H), 7.32-7.33 (m, 1H), 
7.40 (t, exch 1H, J = 6.2), 7.90 (s, 1H). Anal. calcd. for (C14H11N5OS2): C, 51.05%; H, 3.37%; N, 
21.26%. Anal. found: C, 50.90%; H, 3.44%; N, 21.02%. 
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5.1.1.2. 2-(Furan-2-yl)-N5-(furan-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 5. 
The crude product was purified by column chromatography (eluting system: cyclohexane/ethyl 
acetate 3/7), and then by crystallization. Yield 43%. Mp 220-224 °C (ethanol). 1H NMR: δ 4.47 
(d, 2H, J = 6.0), 6.24-6.25 (m, 1H), 6.35-6.37 (m, 1H), 6.71-6.72 (m, 1H), 7.05-7.07 (m, 1H), 7.23-
7.27 (br m, exch 3H), 7.55 (s, 1H), 7.90 (s, 1H). Anal. calcd. for (C14H11N5O2S): C, 53.66%; H, 
3.54%; N, 22.35%. Anal. found: C, 53.71%; H, 3.68%; N, 22.43%. 
5.1.1.3. 2-(Furan-2-yl)-N5-(pyridin-3-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 6. 
Yield  81%. Mp 212-215 °C (ethanol) 1H NMR: δ 4.60 (d, 2H, J = 6.1), 6.71-6.72 (m, 1H), 7.04-
7.05 (m, 1H), 7.22-7.25 (m, exch 2H + 1H), 7.31 (d, 1H, J = 7.9), 7.37 (br s, exch 1H), 7.73 (t, 1H, 
J = 7.6), 7.89 (s, 1H), 8.50-8.51 (m, 1H). Anal. calcd. for (C15H12N6OS): C, 55.54%; H, 3.73%; N, 
25.91%. Anal. found: C, 55.73%; H, 3.94%; N, 26.07%. 
5.1.1.4. 2-(Furan-2-yl)-N5-(thiophen-3-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 7. 
The crude product was purified by column chromatography (eluting system: ethyl acetate, 
cyclohexane/methanol 5/5/2) and then by crystallization. Yield 53%. Mp 209-212°C (ethyl 
acetate). 1H NMR: δ 4.47 (d, 2H, J= 6.1), 6.72 (dd, 1H, J = 3.3, 1.7), 7.05-7.06 (m, 1H), 7.10 (br 
s, exch 1H), 7.22 (br s, exch 2H), 7.29-7.32 (m, 2H), 7.45 (dd, 1H, J = 4.8, 3.0), 7.89-7.90 (m, 1H). 
Anal. calcd. for (C14H11N5OS2): C, 51.05%; H, 3.37%; N, 21.26%. Anal. found: C, 51.30%; H, 
3.45%; N, 21.59%. 
5.1.1.5. 2-(Furan-2-yl)-N5-(pyridin-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 8. 
Yield 74%. Mp 213-217 °C (ethanol) 1H NMR: δ 4.62 (d, 2H,  J=5.9), 6.71-6.74 (m, 1H), 7.05-
7.09 (m, 1H), 7.25-7.40 (m, exch 3H + 2H), 7.77-7.81 (m, 1H), 7.87-7.90 (m, 1H), 8.50-8.52 (m, 
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1H). Anal. calcd. for (C15H12N6OS): C, 55.54%; H, 3.73%; N, 25.91%. Anal. found: C, 55.61%; 
H, 3.65%; N, 25.82%. 
5.1.1.6. 2-(Furan-2-yl)-N5-(pyridin-4-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 9. 
The crude product was purified by column chromatography (eluting system: ethyl 
acetate/methanol 9/2.5). Yield 60%. Mp: 223-225 °C. 1H NMR: δ 4.51 (d, 2H, J= 6.0) 6.71-6.72 
(m, 1H), 7.04-7.05 (m, 1H), 7.23 (s, exch 2H), 7.30-7.31 (m, 2H), 7.47 (br s, exch 1H), 7.89-7.90 
(m, 1H), 8.47-8.48 (m, 2H). Anal. calcd. for (C15H12N6OS): C, 55.54%; H, 3.73%; N, 25.91%. 
Anal. found: C, 55.63%; H, 3.86%; N, 25.75%. 
5.1.1.7. 2-(Furan-2-yl)-N5-(pyrazin-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 10. 
Yield 65%. Mp: 236-238 °C (acetic acid/ethanol). 1H NMR: δ 4.63 (d, 2H, J= 6.1), 6.72 (dd, 1H, 
J = 3.4, 1.7), 7.05-7.06 (m, 1H), 7.27 (s, exch 2H), 7.48 (br s, exch 1H), 7.89-7.90 (m, 1H), 8.50-
8.51 (m, 1H), 8.57-8.58 (m, 1H), 8.62 (s, 1H). Anal. calcd. for (C14H11N7OS): C, 51.68%; H, 
3.41%; N, 30.14%. Anal. found: C, 51.77%; H, 3.50%; N, 30.20%. 
5.1.1.8. 2-(Furan-2-yl)-N5-[2-(thiophen-2-yl)ethyl][1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 
11.  
Yield 78%. Mp 216-218  °C (nitromethane) 1H NMR: δ 3.06 ( t, 2H, J = 7.2), 3.51(dd, 2H, J =13.4, 
7.0), 6.71-6.72 (m, 1H), 6.92-6.96 (m, 3H), 7.04-7.05 (m, 1H), 7.18 (br s, exch 2H),7.32-7.34 (m, 
exch 1H), 7.89-7.90 (m, 1H). Anal. calcd. for (C15H13N5OS2): C, 52.46%; H, 3.82%; N, 20.39%. 
Anal. found: C, 52.74%; H, 3.93%; N, 20.65%. 
5.1.1.9. 2-(Furan-2-yl)-N5-[2-(furan-2-yl)ethyl][1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 12. 
The crude product was purified by column chromatography (eluting system: ethyl 
acetate/cyclohexane 1/1). Yield 82%. Mp 198-200 °C. 1H NMR: δ 2.87 (t, 2H, J= 7.0), 3.51-3.53 
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(m, 2H), 6.17-6.18 (m, 1H), 6.35-6.36 (m, 1H), 6.71-6.72 (m, 1H), 6.90 (br s, exch 1H), 7.04-7.05 
(m, 1H), 7.17 (br s, exch 2H), 7.51-7.52 (m, 1H), 7.88-7.89 (m, 1H). Anal. calcd. for 
(C15H13N5O2S): C, 55.03%; H, 4.00%; N, 21.39%. Anal. found: C, 55.22%; H, 4.13%; N, 21.42%. 
5.1.1.10. 2-(Furan-2-yl)-N5-[2-(pyridin-3-yl)ethyl][1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 
13.  
The crude product was purified by column chromatography (eluting system: ethyl 
acetate/cyclohexane/methanol 8/1/1). Yield 50%. Mp 176-178 °C. 1H NMR: δ 2.87 (t, 2H, J = 
7.0), 3.50 (dd, 2H, J = 12.9, 6.7), 6.72-6.73 (m, 1H), 6.95 (br s, exch 1H), 7.04-7.05 (m, 1H,), 7.18 
(br s, exch 2H), 7.30 (dd, 1H, J = 7.6, 4.7), 7.68 (d, 1H, J = 6.6), 7.89-7.90 (m, 1H), 8.40 (d, 1H, J 
= 4.7), 8.47 (s, 1H). Anal. calcd. for (C16H14N6OS): C, 56.79%; H, 4.17%; N, 24.84%. Anal. found: 
C, 56.45%; H, 4.01%; N, 24.99%. 
5.1.1.11. N5-(2-Methoxybenzyl)-2-(5-methylfuran-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-
diamine 14.  
Yield 70%. Mp 215-217 °C (acetic acid/ethyl acetate). 1H NMR: δ 2.37 (s, 3H), 3.82 (s, 3H), 4.47 
(d, 2H, J = 6.4), 6.32-6.34 (m, 1H), 6.87 (t, 1H, J = 7.5), 6.93-6.98 (m, 2H), 7.05 (br s, exch 1H), 
7.13 (br s, exch 2H), 7.18-7.22 (m, 2H). Anal. calcd. for (C18H17N5O2S): C, 58.84%; H, 4.66%; N, 
19.06%. Anal. found: C, 58.89%; H, 4.44%; N, 19.21%. 
5.1.1.12. N5-(3-Methoxybenzyl)-2-(5-methylfuran-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-
diamine 15. 
Yield 40%. Mp 196-198 °C (ethyl acetate/ ethylene glycol monomethyl ether). 1H NMR: δ 2.37 
(s, 3H), 3.72 (s, 3H), 4.46 (d, 2H, J= 5.6), 6.32-6.34 (m, 1H), 6.76-6.78 (m, 1H), 6.88-6.89 (m, 
 16 
2H), 6.92-6.93 (m, 1H), 7.16 (broad s, exch 2H), 7.19-7.22 (m, 1H), 7.32 (broad s, exch 1H). 13C 
NMR: δ 13.92, 44.57, 55.39, 109.46, 111.45, 112.23, 113.18, 119.68, 129.64, 142.87, 147.10, 
154.57, 157.36, 159.68, 160.31. Anal. calcd. for (C18H17N5O2S): C, 58.84%; H, 4.66%; N, 19.06%. 
Anal. found: C, 58.96%; H, 4.78%; N, 18.79%. 
5.1.1.13. 2-(5-Methylfuran-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-
diamine 16.  
The crude product was purified by column chromatography (eluting system: ethyl 
acetate/cyclohexane 1/1).Yield 80%. Mp 200-203 °C. 1H NMR: δ 2.38 (s, 3H), 4.63 (d, 2H, J = 6), 
6.33-6.34 (m, 1H), 6.94-6.95 (m, 2H), 6.98-6.99 (m, 1H), 7.19 (s, exch 2H), 7.32-7.35 (m, 1H), 
7.36 (broad s, exch 1H). 13C NMR: δ 13.91, 109.46, 111.55, 124.90, 125.31, 126.96, 144.45, 
145.99, 147.09, 154.62, 157.39, 159.91, 164.78. Anal. calcd. for (C15H13N5OS2): C, 52.46%; H, 
3.82%; N, 20.39%. Anal. found: C, 52.33%; H, 4.10%; N, 20.24%. 
5.1.1.14. N5-(2-Methoxybenzyl)-2-(thiophen-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 17. 
Yield 72%. Mp 186-188 °C (acetic acid). 1H NMR: δ 3.82 (s, 3H), 4.47-4.48 (d, 2H, J = 6.2), 6.88 
(t, 1H, J = 7.4), 6.97 (d, 1H, J=7.9), 7.12-7.22 (m, exch 3H + 3H), 7.57-7.59 (m, 1H), 7.72-7.74 
(m, 1H). 13C NMR: δ 55.70, 110.68, 120.50, 127.48, 127.93, 128.00, 128.43, 128.75, 129.33, 
137.50, 157.05, 157.25, 160.58. Anal. calcd. for (C17H15N5OS2): C, 55.26%; H, 4.09%; N, 18.96%. 
Anal. found: C, 55.48%; H, 4.24%; N, 19.05%. 
5.1.1.15. N5-(3-Methoxybenzyl)-2-(thiophen-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diamine 18. 
Yield 40%. Mp 148-150 °C (acetic acid). 1H NMR: δ 3.72 (s, 3H), 4.47 (d, 2H, J= 6.3), 6.76-6.78 
(m, 1H), 6.89-6.90 (m, 2H), 7.13-7.23 (m, exch 2H + 2H), 7.36 (br s, exch 1H), 7.58-7.59 (m, 1H), 
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7.73-7.74 (m, 1H). Anal. calcd. for (C17H15N5OS2): C, 55.26%; H, 4.09%; N, 18.96%. Anal. found: 
C, 55.38%; H, 4.15%; N, 19.12%. 
5.1.1.16. 2-(Thiophen-2-yl)-N5-(thiophen-2-yl-methyl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-
diamine 19. 
 Yield 70%. Mp 208-210 °C (acetic acid). 1H NMR: δ 4.64 (d, 2H, J = 5.1), 6.93-6.98 (m, 1H), 
7.00-7.01 (m, 1H), 7.17-7.23 (m, 3H, exch 2H + 1H), 7.32-7.34 (m, 1H), 7.45 (br s, exch 1H), 
7.61-7.62 (m, 1H) 7.73-7.75 (m, 1H). Anal. calcd. for (C14H11N5S3): C, 48.64%; H, 3.21%; N, 
20.27%. Anal. found: C, 48.57%; H, 3.39%; N, 20.41%. 
5.1.2. General procedure for obtaining 5-chloro-thiazolo[5,4-d]pyrimidin-7-amine derivatives 
(21-22). 
A suspension of the 5,7-dichloro-thiazolo[5,4-d]pyrimidine derivatives 26-27 (3 mmol) in a 
mixture of 33% aqueous ammonia solution (15 mL) and ethanol (15 mL) was refluxed for 6h. The 
mixture was cooled at rt, and the solid was collected by filtration and recrystallized. 
5.1.2.1. 5-Chloro-2-(5-methylfuran-2-yl)[1,3]thiazolo[5,4-d]pyrimidin-7-amine 21. 
Yield 75%. Mp >300 °C (dimethylformamide/water). 1H NMR: δ 2.39 (s, 3H), 6.40-6.41 (m, 1H), 
7.17-7.18 (m, 1H), 8.20 (br s, exch 2H). Anal. calcd. for (C10H7ClN4OS): C, 45.03%; H, 2.65%; 
N, 21.01%. Anal. found: C, 45.31%; H, 2.99%; N, 21.23%. 
5.1.2.2.  5-Chloro-2-(thiophen-2-yl)[1,3]thiazolo[5,4-d]pyrimidin-7-amine 22. 
Yield 70%. Mp >300 °C (2-methoxyethanol). 1H NMR: δ 7.23-7.25 (m, 1H), 7.82-7.83 (m, 
1H),7.88-7.89 (m, 1H) 8.13 (br s, exch 1H), 8.28 (br s,  exch 1H) Anal. calcd. for (C9H5N4ClS2): 
C, 40.22%; H, 1.88%; N, 20.85%. Anal. found: C, 40.51%; H, 2.03%; N, 20.97%. 
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5.1.3. General procedure for obtaining thiazolo[5,4-d]pyrimidine-5,7-diol derivatives (24-25). 
To a suspension of the amino-6-sulfanylpyrimidine-2,4-diol 23 [22] (8 mmol) in NMP dry, the 
proper carbonyl choride (8 mmol) was slowly added. The mixture was heated at 150 °C under N2 
atmosphere for 14 h, and then cooled to rt. Addition of water (100 mL) afforded a precipitate, 
which was collected by filtration and purified by crystallization. 
5.1.3.1. 2-(5-Methylfuran-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diol 24.  
Yield 90%. Mp > 300 °C (dimethylformamide/water). 1H NMR: δ 2.37 (s, 3H), 6.35-6.37 (m, 1H), 
7.06-7.08 (m, 1H), 11.38 (s, exch 1H), 12.06 (br s, exch 1H). Anal. calcd. for (C10H7N4O3S): C, 
48.19%; H, 2.83%; N, 16.86%. Anal. found: C, 48.33%; H, 2.99%; N, 17.05%. 
5.1.3.2. 2-(Thiophen-2-yl)[1,3]thiazolo[5,4-d]pyrimidine-5,7-diol 25.  
Yield 75%. Mp >300 °C (dimethylformamide). 1H NMR: δ 7.17-7.19 (m, 1H), 7.70-7.71 (m, 1H), 
7-77-7.78 (m, 1H), 11.37 (s, exch 1H), 12.08 (br s, exch 1H) Anal. calcd. for (C9H5N4O2S2): C, 
43.02%; H, 2.01%; N, 16.72%. Anal. found: C, 42.87%; H, 2.36%; N, 16.88%. 
5.1.4. General procedure for obtaining 5,7-dichloro-thiazolo[5,4-d]pyrimidine derivatives (26-
27).  
A suspension of the proper 5,7-dihydroxy derivative 24-25 (6 mmol) in POCl3 (20 mL) was 
microwave irradiated at 170 °C for 40 min. The organic phase was concentrated under vacuum, 
the material was taken up twice with cyclohexane (20 mL) and the organics evaporated. The 
residue was added with ice-water (100 g) affording a precipitate, which was collected by filtration 
and used in the next step without further purification. 
5.1.4.1. 5,7-Dichloro-2-(5-methylfuran-2-yl)[1,3]thiazolo[5,4-d]pyrimidine 26.  
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Yield 65%. 1H NMR: δ 2.46 (s, 3H), 6.55-6.57 (m, 1H), 7.56-7-57 (m, 1H). 
5.1.4.2. 5,7-Dichloro-2-(thiophen-2-yl)[1,3]thiazolo[5,4-d]pyrimidine 27.  
Yield 75%. 1H NMR: δ 7.32-7.33 (m, 1H), 8.07-8.10 (m, 2H). 
 
5.2. In vitro pharmacology.  
5.2.1. Materials. 
[3H]-DPCPX ([3H]1,3-dipropyl-8-cyclopentyl-xanthine; specific activity, 120 Ci/mmol), [125I]-
ABMECA ([125I]4-aminobenzyl-5'-N-methyl-carboxamidoadenosine; specific activity, 2200 
Ci/mmol), and [3H]cyclic AMP ([3H]cyclic adenosine monophosphate; specific activity, 22 
Ci/mmol) were obtained from Perkin Elmer Research Products (Boston, MA); [3H]-1 ([3H](4-(2-
[7-amino-2-(2-furil)[1,2.4] triazolo[2,3-a][1,3,5]triazin-5-ylamino] ethyl) phenol); specific 
activity, 17 Ci/mmol) was obtained from Biotrend (Cologne, Germany). DPCPX, NECA (N-
ethylcarboxamido adenosine), AB-MECA, 28 and 1 were obtained from Sigma Aldrich (St. Louis, 
MO).  
5.2.2. Cell culture and membrane preparation. 
Cell culture and membrane preparation from Chinese Hamster Ovary (CHO) cells transfected with 
hA1, hA2A, hA2B and hA3 ARs were previously described [19]. Briefly, the cells were cultured in 
Dulbecco’s modified Eagle’s medium F12 until membrane preparation or the utilization in cAMP 
experiments.   
 
5.2.3. Competition binding experiments.  
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All synthesized compounds were tested for their affinity to hA1, hA2A and hA3 ARs and 
competition binding experiments were carried out as previously described [19]. In particular, 
inhibition experiments to A2A ARs were performed incubating the membrane suspension (50 μg 
of protein/100 μl) with the radioligand [3H]-1 (1 nM) in the presence of different concentrations 
of the tested compounds for 60 min at 4°C in 50 mM TrisHCl (pH 7.4), 10 mM MgCl2. Non-
specific binding was defined as binding in the presence of 1 (1 μM) and was about 20% of the total 
binding [33].  
5.2.4. Cyclic AMP assays. 
In CHO cells transfected with hA2B ARs, cAMP assays were performed in order to evaluate the 
potency of the novel compounds in the inhibition of cAMP levels stimulated by NECA (100 nM). 
The potency and efficacy of the examined compounds were also evaluated for hA2AARs 
investigating their capability to inhibit cAMP levels in both basal conditions and stimulated by 
compound 28 at the 10 nM concentration. Additional experiments were carried out evaluating the 
tested compounds at the 10 µM concentration in hA1, hA2B or hA3CHO cells to verify their effect 
on cAMP production in basal condition. The measurement of cAMP levels was performed by 
using a competition protein binding assay with [3H]-cAMP as previously described in details [19]. 
5.2.5. Statistical analysis. 
The protein concentration was determined according to a Bio-Rad method with bovine albumin as 
a standard reference [34]. The data are expressed as the mean ± SEM of n = 4 independent 
experiments. Statistical analysis of the data was performed using one way ANOVA followed by 
Dunnett’s post hoc test. Inhibitory binding constants, Ki, will be calculated from the IC50 values 
according to the Cheng and Prusoff equation: Ki = IC50/(1 + [C*]/KD*), where [C*] is the 
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concentration of the radioligand and KD* its dissociation constant [36]. KH and KL were obtained 
by fitting binding data to a two sites binding model by using Graph PAD Prism (San Diego, CA, 
USA). IC50 values obtained in cAMP assays were calculated by non-linear regression analysis 
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Figure 1. ZM 241385 1, previously reported thiazolo[5,4-d]pyrimidine 2 and 3, and the newly 
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Figure 2. Competition curves of specific [3H]-1 binding to hA2A ARs of compounds 4 (A), 5 (B), 
6 (C) and 11 (D) characterized by biphasic curves. Data represent means ± SEM of four 

















































































































Figure 3.  Inhibition of cAMP levels in hA2A CHO cells by compounds 4 (A), 5 (B), 6 (C) and 
11 (D). Drug effects are expressed as a percentage of cAMP production in basal conditions. Data 











































































































































































Figure 4. Inhibition of cAMP levels in h A2A CHO cells by compounds 4 (A), 5 (B), 6 (C) and 
11 (D). Drug effects are expressed as a percentage of cAMP production in the presence agonist 








  20 R2 = 2-furanyl                                     4-19 
  21 R2 = 5-methyl-2-furanyl                for R2 and R5 see Table1 
  22 R2 = 2-thienyl 
 



























a Reagents and conditions: a) R2COCl, NMP, 160 °C, (70-90 %); b) POCl3, MW, 170 °C, 40 min, 





24, 26, 21 5-methyl-2-furanyl 






























Table 1. Affinity (Ki or KH, KL) and potency (IC50) of novel compounds in comparison with 










Ki (nM) or KH* 









4 2-furanyl CH2(2-thienyl) 12.5±1.1 10.7±1.0 * 
3.82±0.31 ** 
 
6.43±0.58 75 ±8 








7 2-furanyl CH2(3-thienyl) 
 
8.12±0.71 0.25±0.02 3.14±0.29 8.96±0.82 
8 2-furanyl CH2(2-pyridyl) 
 
28±3 0.42±0.04 59±5 95±9 
9 2-furanyl CH2(4-pyridyl) 
 
47±4 12±1 827±48 33±2 
10 2-furanyl CH2(2-pyrazinyl) 
 
25±4 5.14±0.48 157±14 13.2±1.2 




12 2-furanyl CH2CH2(2-furanyl) 
 


















Affinity values obtained from displacement of specific [3H]DPCPX [a], [3H]-1[b] or [125I]AB- 
MECA [c] binding to hA1ARs, hA2AARs or A3ARs, respectively (n = 3-6). Percentage of 
inhibition (I%) is determined at 10 µM concentration of the tested compounds. [d] Potency (IC50) 











13 2-furanyl CH2CH2(3-pyridyl) 
 










70±6 144±12 160±13 120±11 
16 5-methyl-
2-furanyl 
CH2(2-thienyl) 71±6 34±3 15.3±1.4 91±9 
17 2-thienyl CH2(2-methoxyphenyl) 
 
17.3±1.5 2.24±0.21 275±22 4571±328 
18 2-thienyl CH2(3-methoxyphenyl) 
 
37±4 22±2 430±36 2773±214 
19 2-thienyl CH2(2-thienyl) 
 
73±6 10.1±1.1 38±4 547±47 












Table 2. Potency (IC50) and Efficacy (Emax) of the tested compounds in comparison with 
reference compounds 2, and 3 on cyclic AMP assays in hA2ACHO cells. 
compound IC50 (nM)
[a] Emax (%)[b] IC50 (nM)
[c] Emax (%)[d] 
4 0.0017±0.0002 61±6 0.036±0.003 132±12 
5 0.0016±0.0002 64±6 0.040±0.004 133±13 
6 0.011±0.001 61±5 0.059±0.006 126±12 
7 0.36±0.04 67±6 0.41±0.03 137±13 
8 0.68±0.06 54±5 1.3±0.1 128±11 
9 15.3±1.2 43±4 18.7±1.6 122±10 
10 8.27±0.72 48±4 11.3±0.96 117±10 
11 0.0064±0.0005 62±6 0.045±0.004 138±13 
12 2.93±0.22 56±6 4.26±0.37 121±11 
13 0.29±0.03 71±7 0.35±0.04 141±14 
17 3.36±0.27 62±6 4.41±0.39 129±11 
19 13.2±1.2 44±4 17.6±1.5 115±9 
2[e] 0.0019±0.0002 63±5 0.051±0.004 138±12 
3[e] 0.0083±0.0007 41±3 0.095±0.008 136±11 
1 1.24±0.29 43±3 0.83±0.075 121±10 
Potency (IC50) [a,c] and Efficacy (Emax) [b,d] of the tested compounds in the absence [a,b] or in 






Table 3. Capability of the tested compounds in comparison with reference compounds 2, and 3 to 
modulate cyclic AMP production in hA1CHO cells, hA2BCHO cells and hA3CHO cells. 
The data, expressed as mean ± SEM, indicate the percentage of cAMP modulation over basal level 




hA1CHO cells  hA2BCHO cells  hA3CHO cells 
4 98±7 99±6 96±6 
5 101±9 101±8 104±7 
6 96±6 97±6 100±8 
7 98±6 99±7 105±7 
8 103±8 98±8 101±7 
9 103±7 103±9 102±7 
10 102±7 102±9 98±8 
11 100±9 99±8 94±7 
12 95±7 103±6 97±6 
13 102±8 97±6 102±7 
17 99±7 106±9 103±9 
19 97±8 96±8 99±8 
2[a] 106±8 91±8 94±8 
3[a] 104±8 106±8 99±8 











Property Preferred values Calculated values 
  4 5 6 11 
MW < 500 329.41 313.342 324.369 343.437 
LogP <5 3.6021 3.13.36 2.9356 3.6446 
H donors ≤ 5 2 2 2 2 
H acceptors ≤ 10 8 8 8 8 
Rotable 
bonds ≤ 10 4 4 4 5 
Surface 
area < 140 133.216 128.37 134.795 139.581 
